Tao et al.’s research on the mechanism of MeCP2 action showed that the use of MeCP2 inhibitors to treat cardiac fibroblasts can increase the expression of dual-specificity phosphatase 5 (DUSP5), and DUSP5 negatively regulates the ERK signaling pathway, thus promoting myocardial fibrosis [39]. Here, DUSP5 is linked to Myocardial fibrosis.